Shanxi Zhendong Pharmaceutical (300158)
- 5.01
- -0.05-0.99%
300158 Stock Chart
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
300158 Orderflow
300158 Orderflow Trend
No Data
Shanxi Zhendong Pharmaceutical (300158) News
Zhen Dong Pharmaceutical (300158.SZ): The fifth phase of the employee stock ownership plan has completed its stock purchases.
Gelonghui, May 12th ┃ Zhen Dong Pharmaceutical (300158.SZ) announced that as of the date of this announcement, the company's fifth-phase employee stock ownership plan has cumulatively purchased 9.238 million shares of the company’s stock through the secondary market using centralized competitive bidding, accounting for 0.93% of the company’s total share capital. The total transaction amount was 54.99 million yuan (excluding transaction fees), with an average purchase price of approximately 5.9530 yuan per share. The actual subscribed portion of this stock ownership plan did not exceed the proposed upper limit approved by the shareholders’ meeting.
The dual drivers of the silver economy and the younger generation's focus on health have made the tonic category the main growth engine of the traditional Chinese medicine industry.
① According to the annual report data disclosed by listed companies in 2025, tonic medicines have become the most certain growth track in the traditional Chinese medicine industry; ② Judging from the new product layouts of various proprietary Chinese medicine enterprises, the level of emphasis placed on the tonic track by these companies has also significantly increased.
Zhendong Pharmaceutical: First Quarter Report for 2026
Zhendong Pharmaceutical: Summary of the 2025 Annual Report
Zhendong Pharmaceutical: 2025 Annual Report
Zhen Dong Pharmaceutical (300158.SZ) reported its first-quarter performance, turning from a profit to a loss of 1.0459 million yuan.
Zhen Dong Pharmaceutical (300158.SZ) released its first-quarter report for 2026. The company's operating revenue was 649 million yuan, representing a year-on-year decrease of 13.97%. The net loss attributable to shareholders of the listed company amounted to 1.0459 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 11.1124 million yuan. The basic loss per share was 0.0011 yuan.